SAN DIEGO, August 25, 2026, 07:25 PDT
- Kura stock was at $13.50, rising 8.87%, as of 10:25 EDT.
- Chief Executive Troy Wilson acquired 200,000 shares over eight days, spending $2.351 million.
- KOMZIFTI’s product sales for the quarter increased by 57%, reaching $9.1 million.
Kura Oncology, Inc. NASDAQ:KURA surged 8.87% on Tuesday following a second significant open-market buy from its CEO. The stock was last at $13.50 as of 10:25 EDT, with volume at 1.89 million shares. Kura also reached an all-time intraday peak of $13.73.
The more significant indicator goes beyond just Tuesday’s transaction. Troy Wilson acquired 200,000 shares over eight sessions, spending $2.351 million. At Tuesday’s quoted price, the total value of those shares stood at approximately $2.70 million.
This results in an unrealized profit of approximately $349,000, or 14.8%. The average price paid was $11.755 per share. Wilson acquired shares at $11.12 on August 17 and $12.39 on August 24.
The most recent filing indicates Wilson’s revocable trust contains 479,194 shares. Additionally, 435,456 shares are held directly, with another 300,000 held via a charitable trust. His reported beneficial ownership amounts to 1,214,650 shares, with an approximate value of $16.4 million at Tuesday’s closing price.
Wall Street sentiment was widely optimistic. Prior to Tuesday’s increase, the consensus target among 15 analysts stood at $32. That figure is still 137% higher than the current quoted price, with published targets ranging from $15 to $76.
| Analyst | Date | Recommendation | Target |
|---|---|---|---|
| Wedbush | Aug. 13, 2026 | Outperform | $38 |
| Bank of America | Aug. 13, 2026 | Buy | $31 |
| Citizens | June 15, 2026 | Market Outperform | $24 |
| Lake Street | April 14, 2026 | Buy | $23 |
| Mizuho | March 24, 2026 | Outperform | $25 |
KOMZIFTI, Kura’s debut commercial product, is central to the valuation argument. Net product revenue for the second quarter was $9.1 million, marking a 57% sequential increase. New patient starts climbed 35% to approximately 115, and total prescriptions grew 59% to surpass 250.
“In just its second complete quarter since launch, KOMZIFTI demonstrated initial leadership,” Wilson stated in the results statement. The company said it captured the majority of new starts in its authorized menin-inhibitor segment.
Commercial progress is modest compared to expenditures. Second-quarter total revenue totaled $20.9 million, and operating expenses amounted to $93.9 million. Kura reported a net loss of $68.3 million.
The balance sheet provides a buffer. As of June 30, cash and short-term investments stood at $519.0 million. Kura is anticipating an additional $180 million from Kyowa Kirin, with management stating that this funding will support the ziftomenib program through the first pivotal Phase 3 data readout in 2028.
Tuesday’s surge brought Kura’s market capitalization to approximately $1.20 billion. Wilson’s newly acquired shares make up just 0.22% of the total shares in circulation. The significance of these shares is tied to their valuation and frequency, rather than any influence over voting rights.
The upcoming test concerns operational proof. Continued increases in prescriptions need to close the gap separating product revenue from research outlays. Clinical updates anticipated in the second half may also alter development likelihoods.
Risks: Insider purchases do not ensure gains. The rollout of KOMZIFTI could decelerate, clinical studies might not succeed, and setbacks could lead to a need for additional funding even with Kura’s present cash reserves.
Related articles: Stock Market
